Specialist cancer drug discovery company, Sareum, and oncology-focused development and commercialisation company, Cancer Research Technology Limited, last week announced the publication of the latest results from their joint research collaboration with The Institute of Cancer Research. The results were presented at the National Cancer Research Institute Cancer Conference, in Birmingham, UK.

Of particular interest was data showing how the drug candidate Chk1 (Checkpoint Kinase 1) can produce up to twofold increases in the efficacy of marketed cancer chemotherapeutics.

Sareum is developing seven early-stage cancer drug programmes, one of which is ready for licensing and two are close to licensing. Chk1 is the most advanced and we believe that, as with some other Sareum cancer programmes, it is attracting interest from potential licensees.

Major pharmaceuticals groups have a well-known need to build their cancer drug pipelines and to bring drugs to market quickly. We believe Sareum can be expected to react even more positively to any good news, particularly were the company to sign a deal.

Chk1 Cancer Research Programme to be presented

at the NCRI Cancer Conference 2009

Sareum (Sareum or the Company), the specialist cancer drug discovery business and Cancer Research Technology Limited (CRT), the oncology focused development and commercialisation company, are pleased to announce publication of the latest results from their joint research collaboration with The Institute of Cancer Research (The ICR).

Later today, a poster entitled Biological Properties of the Novel Chk1 Inhibitor SAR-020106 will be presented at the National Cancer Research Institute (NCRI) Cancer Conference, which is being held in Birmingham, UK. Of particular interest will be data that shows how this drug candidate, developed by Sareum and The ICR, can produce up to 2-fold increases in the efficacy of marketed cancer chemotherapeutics.

The science that leads to the development of this compound was recently published in the Journal of Medicinal Chemistry*. This paper describes how Sareums expertise in fragment and structure-based drug discovery combined with cancer biology and medicinal chemistry expertise at The Institute successfully identified novel inhibitors of Chk1 (Checkpoint Kinase 1).

Chk1, the target of the joint research collaboration, is a key component of a biochemical pathway responsible for preventing the effectiveness of traditional cancer therapeutics such as chemotherapy. The aim of the collaboration is to develop novel cancer treatments with the potential to have efficacy against tumours which do not respond to chemotherapy and/or cause fewer adverse side-effects as a result of lower doses of chemotherapy being required.

Compounds with activity against cancer kinases available for licensing

Science|Business

Licensing opportunity

Sareum Holdings plc, a structure-based drug discovery specialist has developed and filed patents on novel small molecule compounds which show promising activity against two significant cancer drug targets, the Aurora and FLT kinases. Chief Executive Officer, Tim Mitchell, said, We are actively seeking licensing partners for this programme to assist the advancement of these novel chemical series through to clinical candidate nomination.

These are believed to be key to the regulation of cell division and proliferation that controls different stages in the development of a tumour. It is thought that a drug simultaneously able to inhibit the function of both...

blast!!! looked at this early today - kicking myself - didnt bother as already up 20% + early expected quick retrace as normal same day - lol misread this completely!!! i'm expecting a retrace tomorrow which must now mean it will go up even further!! drat - drat & double drat!!

but good luck to any who made here today - not a bad little share - wonder if pyc will reciprocate soon!!! gla

lol lol lol lol

didnt miss it today - kerrrrrrrrrrrchinnnnnggggggggggggggaroooooooooooooooooooooooooooooooo!!

next stop 1p - yeeeeeeeeeeeeehaaaaaaaaaaaaaaaaaaaaaa!!!!!

yeeeeeeeeeeeeeeeeeeeehaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

think i'll take me the rest of this week off lol lol

gla

kerrrrrrrrrrrrrrrrrrrrrrchinnnnnnnnnnnnnnnnnnnnnngggggggggggggggggggggggggg overload!!!

dont forget this flew when US markets opened up yesterday!!!!!!!!!!!!!!!!!!!!!

roll on an hour or 2!!!!!

double yeeeeeeeeeeeeeeeeeeehaaaaaaaaaaaaaaaaaaaaaaaa!!!

roll on 1.5

Well done gibby!!!

M/Cap at 25m now at 1.81


Antisoma Market Cap (m)15

cheers markymar - been a real good day - rrl did well too - very good day at the office today

i hope you managed to make some s here too and had a good day also

hello driver - yes good point ref asm - you say much there in few words - their as1413 failed yet still around 2.3 ish - the asm director buys look a bit sick there now - down sizing ahead i believe for them etc

i was also watching pyc today - but didnt move for 2 reasons - 1 l2 was not strong enough for me for pyc - and about a year or so ago i was locked into the dreaded pyc (dreaded then) for months - a rise not unlike today's came along and i made a swift exit just below break even - so to go back to pyc i would be extremely wary - however it may be a bit of a dark horse tomorrow - take a look at pyc rns from last year - i seem to remember thinking not much of it at the time...... but now? gla and have a good evening

remember I stress this is an rns from last year!! but interesting now - but will need a tad more research...
Collaboration with Sareum,
RNS Number : 5973I

Physiomics PLC

16 March 2010



Physiomics Plc

("Physiomics" or "the Company")

Physiomics to collaborate with Sareum, the ICR and CRT on cancer drug development programme

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, and Sareum Holdings plc (AIM: SAR) are pleased to announce that they have signed an agreement in which Physiomics provides in silico simulations to support Sareum's cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT).

http://www.barchart.com/opinions/stocks/SAR.LS

yeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeehaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
kerrrrrrrrrrrrrrrrrrchingggggggggggggggggggggaroooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo

gla